Nektar Therapeutics will deliver three oral presentations on rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026, the company announced.

The announcement confirms the company's continued investment in the dermatology data cycle for rezpegaldesleukin, an investigational therapeutic that Nektar has positioned within immune-mediated disease programs. Securing three oral slots at EADV — rather than poster presentations — signals that congress reviewers rated the submitted data highly enough for podium sessions, a distinction that typically reflects completed or late-stage trial readouts.

Details of the presentation titles, session dates, and full data sets were not disclosed in the announcement. Nektar has not yet published the specific endpoints, cohort sizes, or efficacy measures that will anchor the three orals, and the congress scientific program typically finalizes speaker scheduling closer to the meeting.

For dermatology clinicians, the EADV 2026 program will be the venue to watch for whatever new rezpegaldesleukin evidence Nektar tables — whether phase 2 extensions, durability follow-up, or dose-optimization analyses. Full presentation abstracts are expected to appear in the EADV congress materials once the scientific committee releases the final agenda.

Rezpegaldesleukin's path through clinical development has drawn interest from the inflammatory skin disease community, where demand persists for therapies with sustained response and convenient administration in conditions such as psoriasis and atopic dermatitis. Whether the three EADV orals address that unmet need directly will become clear only when the data are presented.

Nektar said the presentations will take place at the EADV 2026 Congress; registration and program information will follow through official congress channels.